Combo Impresses in Advanced Bladder Cancer

]]>(MedPage Today) -- SAN FRANCISCO--Patients with cisplatin-ineligible advanced bladder cancer achieved durable objective responses with the combination of pembrolizumab (Keytruda) and a newly approved antibody-drug conjugate (ADC), new data...